17, № 5. 2019

More documents

Recommendations

Info

Том 17, № 5. 2019PRACTICAL MEDICINE 22729. Hyams J.S., Di Lorenzo C., Saps M. et al. Functional disorders:children and adolescents // Gastroenterology. — 2016. — Vol. 150. —P. 1456–1468.30. Ferrara M., Capozzi L., Russo R. Effect of Helicobacter pylorieradication on platelet count in children with chronic idiopathicthrombocytopenic purpura // Hematology. — 2009. — Vol. 14. —P. 282–285.31. Russo G., Miraglia V., Branciforte F. et al. Effect of eradication ofHelicobacter pylori in children with chronic immune thrombocytopenia:a prospective, controlled, multicenter study // Pediatr Blood Cancer. —2011. — Vol. 56. — P. 273–278.32. Brito H.S., Braga J.A., Loggetto S.R. et al. Helicobacter pyloriinfection and immune thrombocytopenic purpura in children andadolescents: a randomized controlled trial // Platelets. — 2015. —Vol. 26. — P. 336–341.33. Calvet X. Diagnosis of Helicobacter pylori infection in theproton pump inhibitor era // Gastroenterol Clin North Am. — 2015. —Vol. 44. — P. 507–518.34. Dixon M.F., Genta R.M., Yardley J.H. et al. Classification andgrading of gastritis. The updated Sydney System. InternationalWorkshop on the Histopathology of Gastritis, Houston 1994 // Am JSurg Pathol. — 1996. — Vol. 20. — P. 1161–1181.35. Rimbara E., Sasatsu M., Graham D.Y. PCR detection ofHelicobacter pylori in clinical samples // Methods Mol Biol. — 2013. —Vol. 943. — P. 279–287.36. Saez J., Belda S., Santibanez M. et al. Real-time PCR fordiagnosing Helicobacter pylori infection in patients with uppergastrointestinal bleeding: comparison with other classical diagnosticmethods // J Clin Microbiol. — 2012. — Vol. 50. — P. 3233–3237.37. Graham D.Y., Lee Y-C., Wu M-S. Rational Helicobacter pyloritherapy: evidence-based medicine rather than medicine-basedevidence // Clin Gastroenterol Hepatol. — 2014. — Vol. 12. —P. 177–186.38. Seo J.H., Jun J.S., Yeom J.S. et al. Changing pattern ofantibiotic resistance of Helicobacter pylori in children during 20 yearsin Jinju, South Korea // Pediatr Int. — 2013. — Vol. 55. — P. 332–336.39. Raymond J., Lamarque D., Kalach N. et al. High level ofantimicrobial resistance in French Helicobacter pylori isolates //Helicobacter. — 2010. — Vol. 15. — P. 21–27.40. Zevit N., Levy I., Shmuely H. et al. Antibiotic resistance ofHelicobacter pylori in Israeli children // Scand J Gastroenterol. —2010. — Vol. 45. — P. 550–555.41. Selgrad M., Tammer I., Langner C. et al. Different antibioticsusceptibility between antrum and corpus of the stomach, a possiblereason for treatment failure of Helicobacter pylori infection // World JGastroenterol. — 2014. — Vol. 20. — P. 16245–16251.42. Wenzhen Y., Yumin L., Quanlin G. et al. Is antimicrobialsusceptibility testing necessary before first-line treatment forHelicobacter pylori infection? Meta-analysis of randomized controlledtrials // Intern Med. — 2010. — Vol. 49. — P. 1103–1109.43. Bontems P., Kalach N., Oderda G. et al. Sequential therapyversus tailored triple therapies for Helicobacter pylori infectionin children // J Pediatr Gastroenterol Nutr. — 2011. — Vol. 53. —P. 646–650.44. Horvath A., Dziechciarz P., Szajewska H. Meta-analysis:sequential therapy for Helicobacter pylori eradication in children //Aliment Pharmacol Ther. — 2012. — Vol. 36. — P. 534–541.45. Horvath A., Dziechciarz P., Szajewska H. Letter: sequentialtherapy for Helicobacter pylori eradication in children updated metaanalysisof randomized controlled trials // Aliment Pharmacol Ther. —2013. — Vol. 37. — P. 835–836.46. Schwarzer A., Bontems P., Urruzuno P. et al. Sequential Therapyfor Helicobacter pylori Infection in Treatment-naive Children //Helicobacter. — 2016. — Vol. 21. — P. 106–113.47. Li B.Z., Threapleton D.E., Wang J.Y. et al. Comparativeeffectiveness and tolerance of treatments for Helicobacter pylori:systematic review and network meta-analysis // BMJ. — 2015. —Vol. 351. — P. h4052.48. Fallone C.A., Chiba N., Veldhuyzen van Zanten S. et al. Clinicalpractise guidelines for the treatment of Helicobacter pylori infection:the Toronto Consensus // Gastroenterology. — 2016.49. Malfertheiner P., Megraud F., O’Morain C.A., et al. Managementof Helicobacter pylori infection-the Maastricht V/Florence ConsensusReport // Gut. — 2017. — Vol. 66. — P. 6–30.50. Камалова А.А. Обоснование и результаты примененияпробиотиков при хронической гастродуоденальной патологии //Практическая медицина. — 2011. — № 1. — С. 86–88.51. Камалова А.А., Хуснуллина Г.А. Опыт применения синбиотическогокомплекса при хронической гастродуоденальной патологииу детей // Педиатрическая фармакология. — 2011. — Т. 8,№ 1. — С. 112–115.52. Li S., Huang X.L., Sui J.Z. et al. Meta-analysis of randomizedcontrolled trials on the efficacy of probiotics in Helicobacter pylorieradication therapy in children // Eur J Pediatr. — 2014. — Vol. 173. —P. 153–161.53. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probioticsupplementation increases Helicobacter pylori eradication rate:evidence from a meta-analysis // Rev Esp Enferm Dig. — 2013. —Vol. 105. — P. 445–453.54. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: theeffects of Saccharomyces boulardii supplementation on Helicobacterpylori eradication rates and side effects during treatment // AlimentPharmacol Ther. — 2010. — Vol. 32. — P. 1069–1079.55. Zeng M., Mao X.H., Li J.X. et al. Efficacy, safety, andimmunogenicity of an oral recombinant Helicobacter pylori vaccinein children in China: a randomised, double-blind, placebo-controlled,phase 3 trial // Lancet. — 2015. — Vol. 386. — P. 1457–1464.56. Guarner J., Kalach N., Elitsur Y. et al. Helicobacter pyloridiagnostic tests in children: review of the literature from 1999 to2009 // Eur J Pediatr. — 2010. — Vol. 169. — P. 15–25.57. Leal Y.A., Flores L.L., Fuentes-Panana E.M. et al. 13C-ureabreath test for the diagnosis of Helicobacter pylori infection inchildren: a systematic review and meta-analysis // Helicobacter. —2011. — Vol. 16. — P. 327–337.58. Pacheco S.L., Ogata S.K., Machado R.S. et al. Diagnosis ofHelicobacter pylori infection by means of reduced-dose 13C-ureabreath test and early sampling of exhaled breath // J PediatrGastroenterol Nutr. — 2013. — Vol. 57. — P. 607–611.59. Leal Y.A., Cedillo-Rivera R., Simon J.A. et al. Utility of stoolsamplebased tests for the diagnosis of Helicobacter pylori infectionin children // J Pediatr Gastroenterol Nutr. — 2011. — Vol. 52. —P. 718–728.60. Zhou X., Su J., Xu G. et al. Accuracy of stool antigen testfor the diagnosis of Helicobacter pylori infection in children: a metaanalysis// Clin Res Hepatol Gastroenterol. — 2014. — Vol. 38. —P. 629–638.
228 ПРАКТИЧЕСКАЯ МЕДИЦИНАТом 17, № 5. 2019УДК 57.083.32КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯВ.А. МАЛИЕВСКИЙ 1 , С.С. ЖУКОВ 1 , Е.П. ПЕРВУШИНА 2 , А.Ж. НУРИАХМЕТОВА 2 , Л.Р. НУРГАЛИЕВА 2 ,Е.Д. ШАКИРЬЯНОВА 2 , А.А. ХАСАНОВА 21Башкирский государственный медицинский университет МЗ РФ г. Уфа2Республиканская детская клиническая больница МЗ РБ, г. УфаПрименение канакинумаба у пациентас системным вариантом ювенильногоидиопатического артрита с непереносимостьютоцилизумаба (клинический случай)Контактная информация:Малиевский Виктор Артурович — доктор медицинских наук, профессор, заведующий кафедрой госпитальной педиатрииАдрес: 450008, г. Уфа, ул. Ленина, д. 3, тел.: +7 (347) 229-08-12, e-mail: vmalievsky@mail.ruЮвенильные артриты — группа наиболее часто встречающихся ревматических заболеваний у детей, с длительнымпрогрессирующим течением, с развитием инвалидизации [1]. В статье представлен клинический случай системного ювенильногоидиопатического артрита (сЮИА) с развитием нежелательного явления на тоцилизумаб. Представленный клиническийопыт свидетельствует о высокой эффективности и безопасности канакинумаба в лечении системного вариантаЮИА у больного с большой длительностью заболевания (11 лет), рефрактерностью к комбинированной базиснойпротиворевматической терапии и непереносимостью тоцилизумаба.Ключевые слова: дети, ювенильный идиопатический артрит, генно-инженерные биологические препараты, аллергическаяреакция.(Для цитирования: Малиевский В.А., Жуков С.С., Первушина Е.П., Нуриахметова А.Ж., Нургалиева Л.Р., ШакирьяноваЕ.Д., Хасанова А.А. Применение канакинумаба у пациента с системным вариантом ювенильного идиопатического артритас непереносимостью тоцилизумаба (клинический случай). Практическая медицина. 2019. Том 17, № 5, С. 228-230)DOI: 10.32000/2072-1757-2019-5-228-230V.A. MALIEVSKY 1, 2 , S.S. ZHUKOV 1 , E.P. PERVUSHINA 2 , A.Zh. NURIAKHMETOVA 2 , L.R. NURGALIEVA 2 ,E.D. SHAKIRYANOVA 2 , A.A. KHASANOVA 21Bashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa2Republic Children’s Clinical Hospital, UfaClinical case of kanakinumab applicationin a patient with systemic juvenile idiopathic arthritiswith tocylisumab inabilityContact details:Malievsky V.A. — MD, Professor, Head of the Department of Hospital PediatricsAddress: 3 Lenin St., Ufa, Russian Federation, 450008, tel.: +7 (347) 229-08-12, e-mail: vmalievsky@mail.ruJuvenile arthritis is the group of the most common rheumatic diseases in children, with a long progressive course and development ofdisability [1]. The article presents a clinical case of systemic juvenile idiopathic arthritis (sJIA), complicated by resistance to a geneticallyengineered drug (GEBAs) — tocilizumab (TCZ). The presented clinical case shows the high efficiency and safety of canakinumab in thetreatment of the systemic variant of JIA in a patient with a long duration of the disease (11 years), refractoriness to the combined basicantirheumatic therapy, and tocilizumab intolerance.Key words: children, juvenile idiopathic arthritis, genetic engineering biological preparations, allergic reaction.(For citation: Malievsky V.A., Zhukov S.S., Pervushina E.P., Nuriakhmetova A.Zh., Nurgalieva L.R., Shakiryanova E.D.,Khasanova A.A. Clinical case of kanakinumab application in a patient with systemic juvenile idiopathic arthritis with tocylisumabinability. Practical Medicine. 2019. Vol. 17, № 5, P. 228-230)
Page 1 and 2:
Научно-практически
Page 3 and 4:
Ï Ì«PRACTICAL MEDICINE» Vol. 17
Page 5 and 6:
4 ПРАКТИЧЕСКАЯ МЕДИ
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
10 ПРАКТИЧЕСКАЯ МЕД
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178: 176 ПРАКТИЧЕСКАЯ МЕД
Page 227: 226 ПРАКТИЧЕСКАЯ МЕД
Page 235: 234 ПРАКТИЧЕСКАЯ МЕД
show all

17, № 5. 2019

Create successful ePaper yourself

Delete template?

Save as template?